bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.03.04.641385

On the Comparability of Studies in Predictive Ecotoxicology

Abstract

Comparability across in silico predictive ecotoxicology studies remains a significant challenge, particularly when assessing model performance. In this work, we identify key criteria necessary for meaningful comparison between independent studies: (i) the use of identical datasets that represent the same chemical and/or taxonomic space; (ii) consistent data cleaning procedures; (iii) identical train/test splits; (iv) clearly defined evaluation metrics, as subtle differences--such as alternative formulations of R2--can lead to misleading discrepancies; and (v) transparent reporting through code and dataset sharing. Our review of recent literature on fish acute toxicity prediction reveals a critical gap: no two studies fully meet these criteria, rendering cross-study comparisons unreliable. This lack of comparability hampers scientific progress in the field. To address this, we advocate for the adoption of benchmark datasets with standardized cleaning protocols, version control, and defined data splits. We further emphasize the importance of precise metric definitions and transparent reporting practices, including code availability and the use of structured reporting or data sheets, to foster reproducibility and advance the discipline.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Schuer, C., Schirmer, K., Baity Jesi, M.. 2025-03-10. On the Comparability of Studies in Predictive Ecotoxicology. https://doi.org/10.1101/2025.03.04.641385

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Preclinical Safety Evaluation of Vernolac, a Commercially Available Polyherbal Nutraceutical Comprising Vernonia zeylanica, Nigella sativa, Hemidesmus indica, Smilax glabra, and Leucas zeylanica, in Wistar Rats

Vernolac is a commercially available polyherbal formulation comprising Vernonia zeylanica aerial parts, Nigella sativa seeds, Hemidesmus indica roots, Smilax glabra rhizome, and Leucas zeylanica aerial parts. Although previous in vitro studies have demonstrated anticancer potential of Vernolac and its active ingredients, safety data are available only for some of the plant ingredients of Vernolac. In the present study, acute and 28-day repeat-dose toxicity of Vernolac were evaluated in Wistar rats following OECD guidelines 420 and 407, respectively. Acute toxic effect was investigated during 14 days after administering a single oral dose of 2000 mg/kg to 10 animals (5 males, 5 female) which was followed by repeat-dose study where a human equivalent therapeutic dose HED (165 mg/kg/day), a mid-dose (2x HED, 330mg/kg/day) and a high dose (4x HED, 660 mg/kg/day) were administered separately to a group of 10 fresh animals (5 male, 5 female) for 28 days. In both acute and repeat-dose studies, no morbidity, mortality, changes in food and water intake, relative organ weights, microscopic changes in organs, hematological changes, or clinical signs of toxicity were observed. In the acute study, significant differences appeared only in AST and ALT levels in males, indicating the liver may be a target organ of toxicity at extremely high doses. In 28-days repeated dose study, a significant reduction in ALT was observed only in females receiving high doses, with no changes in males. In summary, a dose up to four times the therapeutic daily dose is non-toxic in Wistar rats over a 28-day period.

pharmacology and toxicology↗